iShares MSCI South Korea ETF vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? iShares MSCI South Korea ETF trades at $153.76 (market cap $22.66B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $13 (market cap $10.61B). The key difference: iShares MSCI South Korea ETF is far larger — about 2.1× Dr. Reddy's Laboratories Ltd Common Stock's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 48 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| EWY | RDY | |
|---|---|---|
Market Cap | $22.66B | $10.61B |
Volume | 17,900,400 | 3,738,869 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $15.38 |
52-Week Low | $85.17 | $11.38 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $10.51B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $152.24 after an 8.6% decline amid broader Asian market pressures. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though oscillators suggest potential near-term recovery. Recent news highlights South Korea's KOSPI volatility driven by semiconductor sector sensitivity to AI demand, oil prices, and global bond yields.
Outlook remains tied to semiconductor cycle strength and AI infrastructure spending, with risks including concentrated exposure to Samsung and SK hynix, macroeconomic headwinds from rising yields and oil prices, and regional market volatility. The ETF's performance is highly correlated with memory chip demand trends and US-South Korea trade dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →